Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,029 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

40,029 Papers indexed
1,440 Papers AI scored
40,029 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40029 results
B
AI -
Standard 72.1
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 18.0; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
Neurobehavioral outcomes and associated risk factors in pediatric brain tumor survivors.
PMID 41964753 Published: 2026-04-11 Ingested: 2026-08-02 12:06 AM Journal of neuro-oncology
AI -
Standard 72.1
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 38.0; sample size: 70.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Standard 72.1
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 83.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
Endocrine and metabolic consequences of childhood-onset craniopharyngioma during the transition age: A literature review by the TALENT study group.
PMID 40622633 Published: 2025-07-07 Ingested: 2026-08-02 12:04 AM Reviews in endocrine & metabolic disorders
AI -
Standard 72.1
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 28.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
Gonadal function in pediatric female post-Allo-HSCT: a real-life prospective study from China.
PMID 40553563 Published: 2025-06-24 Ingested: 2026-08-02 12:04 AM Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
AI -
Standard 72.1
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 28.0; sample size: 60.0; recency: 90.0; abstract quality: 85.0.

B
Neo-antigen specific cancer vaccines for acute lymphoblastic leukemia-challenges, opportunities, and future directions.
PMID 40550858 Published: 2025-06-23 Ingested: 2026-08-02 12:04 AM Cancer immunology, immunotherapy : CII
AI -
Standard 72.1
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 95.5; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
Implementing Evidence-Based Strategies to Improve Pediatric Oncology Infection Management.
PMID 40446180 Published: 2025-05-30 Ingested: 2026-08-02 12:04 AM American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
AI -
Standard 72.1
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 28.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

Previous
Page 537 of 3336
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic